ID   VGFR3_HUMAN             Reviewed;        1363 AA.
AC   P35916; A8K6L4; B5A926; Q16067; Q86W07; Q86W08;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2011, sequence version 3.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Vascular endothelial growth factor receptor 3;
DE            Short=VEGFR-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 4;
DE            Short=FLT-4;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT4;
DE   Flags: Precursor;
GN   Name=FLT4; Synonyms=VEGFR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=1327515;
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RT   "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like
RT   loops and is expressed in multiple human tissues and cell lines.";
RL   Cancer Res. 52:5738-5743(1992).
RN   [2]
RP   ERRATUM.
RA   Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L.,
RA   Alitalo R., Alitalo K.;
RL   Cancer Res. 53:3845-3845(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1319394; DOI=10.1016/0888-7543(92)90277-Y;
RA   Galland F., Karamysheva A., Mattei M.-G., Rosnet O., Marchetto S.,
RA   Birnbaum D.;
RT   "Chromosomal localization of FLT4, a novel receptor-type tyrosine
RT   kinase gene.";
RL   Genomics 13:475-478(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS GLN-890 AND
RP   HIS-1146.
RC   TISSUE=Placenta;
RX   PubMed=8386825;
RA   Galland F., Karamysheva A., Pebusque M.-J., Borg J.-P., Rottapel R.,
RA   Dubreuil P., Rosnet O., Birnbaum D.;
RT   "The FLT4 gene encodes a transmembrane tyrosine kinase related to the
RT   vascular endothelial growth factor receptor.";
RL   Oncogene 8:1233-1240(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INTERACTION WITH VEGFC,
RP   PHOSPHORYLATION, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=8700872; DOI=10.1073/pnas.93.5.1988;
RA   Lee J., Gray A., Yuan J., Luoh S.-M., Avraham H., Wood W.I.;
RT   "Vascular endothelial growth factor-related protein: a ligand and
RT   specific activator of the tyrosine kinase receptor Flt4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1988-1992(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH VEGFD, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS GLN-890
RP   AND HIS-1146.
RA   Lian Z., Feitelson M.;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   GLN-890.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 761-1190.
RX   PubMed=1310071;
RA   Aprelikova O., Pajusola K., Partanen J., Armstrong E., Alitalo R.,
RA   Bailey S.K., McMahon J., Wasmuth J., Huebner K., Alitalo K.;
RT   "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-
RT   qter.";
RL   Cancer Res. 52:746-748(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1293-1363 (ISOFORM 1), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=7692369;
RA   Pajusola K., Aprelikova O., Armstrong E., Morris S., Alitalo K.;
RT   "Two human FLT4 receptor tyrosine kinase isoforms with distinct
RT   carboxy terminal tails are produced by alternative processing of
RT   primary transcripts.";
RL   Oncogene 8:2931-2937(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [13]
RP   CATALYTIC ACTIVITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=7898938;
RA   Borg J.P., deLapeyriere O., Noguchi T., Rottapel R., Dubreuil P.,
RA   Birnbaum D.;
RT   "Biochemical characterization of two isoforms of FLT4, a VEGF
RT   receptor-related tyrosine kinase.";
RL   Oncogene 10:973-984(1995).
RN   [14]
RP   FUNCTION IN CELL PROLIFERATION AND PHOSPHORYLATION OF SHC1,
RP   CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2, INTERACTION WITH SHC1 AND
RP   GRB2, AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-1333; TYR-1337 AND
RP   TYR-1363, AND TISSUE SPECIFICITY.
RX   PubMed=7675451;
RA   Fournier E., Dubreuil P., Birnbaum D., Borg J.P.;
RT   "Mutation at tyrosine residue 1337 abrogates ligand-dependent
RT   transforming capacity of the FLT4 receptor.";
RL   Oncogene 11:921-931(1995).
RN   [15]
RP   INTERACTION WITH VEGFD, FUNCTION AS VEGFD RECEPTOR, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=9435229; DOI=10.1073/pnas.95.2.548;
RA   Achen M.G., Jeltsch M., Kukk E., Maekinen T., Vitali A., Wilks A.F.,
RA   Alitalo K., Stacker S.A.;
RT   "Vascular endothelial growth factor D (VEGF-D) is a ligand for the
RT   tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:548-553(1998).
RN   [16]
RP   FUNCTION AS RECEPTOR FOR VEGFC AND VEGFD IN CELL SURVIVAL;
RP   PROLIFERATION AND MIGRATION, AND FUNCTION IN ACTIVATION OF PROTEIN
RP   KINASE C; AKT1; PIK3R1; MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=11532940; DOI=10.1093/emboj/20.17.4762;
RA   Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B.,
RA   Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D.,
RA   Stacker S.A., Achen M.G., Alitalo K.;
RT   "Isolated lymphatic endothelial cells transduce growth, survival and
RT   migratory signals via the VEGF-C/D receptor VEGFR-3.";
RL   EMBO J. 20:4762-4773(2001).
RN   [17]
RP   INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   CHARACTERIZATION OF VARIANT LMPH1A PRO-1041, MUTAGENESIS OF LYS-879;
RP   TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337 AND TYR-1363, AND
RP   PHOSPHORYLATION AT TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337
RP   AND TYR-1363.
RX   PubMed=12881528; DOI=10.1074/jbc.M304499200;
RA   Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C.,
RA   Alitalo K., Claesson-Welsh L.;
RT   "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-
RT   3) heterodimerization with VEGFR-2 in primary lymphatic endothelial
RT   cells regulates tyrosine phosphorylation sites.";
RL   J. Biol. Chem. 278:40973-40979(2003).
RN   [18]
RP   FUNCTION IN KDR SIGNALING AND IN ANGIOGENESIS, INTERACTION WITH KDR,
RP   AND PHOSPHORYLATION.
RX   PubMed=15474514; DOI=10.1016/j.bbrc.2004.08.237;
RA   Alam A., Herault J.P., Barron P., Favier B., Fons P.,
RA   Delesque-Touchard N., Senegas I., Laboudie P., Bonnin J., Cassan C.,
RA   Savi P., Ruggeri B., Carmeliet P., Bono F., Herbert J.M.;
RT   "Heterodimerization with vascular endothelial growth factor receptor-2
RT   (VEGFR-2) is necessary for VEGFR-3 activity.";
RL   Biochem. Biophys. Res. Commun. 324:909-915(2004).
RN   [19]
RP   FUNCTION IN CELL SURVIVAL, PHOSPHORYLATION IN RESPONSE TO OXIDATIVE
RP   STRESS, INTERACTION WITH PIK3R1; SHC1; GRB2; PTPN11 AND PLCG1, ENZYME
RP   REGULATION BY MAZ51, AND CHARACTERIZATION OF VARIANT LMPH1A ARG-857.
RX   PubMed=15102829; DOI=10.1074/jbc.M314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [20]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1 AND MAPK8,
RP   FUNCTION IN PROMOTING CELL SURVIVAL; PROLIFERATION AND MIGRATION,
RP   CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2, INTERACTION WITH CRK AND
RP   GRB2, PHOSPHORYLATION AT TYR-1063; TYR-1068; TYR-1230; TYR-1231 AND
RP   TYR-1337, AND MUTAGENESIS OF TYR-1063; TYR-1068; TYR-1230 AND
RP   TYR-1231.
RX   PubMed=16076871; DOI=10.1182/blood-2005-04-1388;
RA   Salameh A., Galvagni F., Bardelli M., Bussolino F., Oliviero S.;
RT   "Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation,
RT   migration, and survival of endothelial cells through the activation of
RT   ERK, AKT, and JNK pathways.";
RL   Blood 106:3423-3431(2005).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-527.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   FUNCTION IN PROMOTING CELL SURVIVAL, INTERACTION WITH PTK2/FAK1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16452200; DOI=10.1158/0008-5472.CAN-05-1661;
RA   Garces C.A., Kurenova E.V., Golubovskaya V.M., Cance W.G.;
RT   "Vascular endothelial growth factor receptor-3 and focal adhesion
RT   kinase bind and suppress apoptosis in breast cancer cells.";
RL   Cancer Res. 66:1446-1454(2006).
RN   [23]
RP   FUNCTION IN LYMPHANGIOGENESIS.
RX   PubMed=17210781; DOI=10.1096/fj.06-6656com;
RA   Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y.,
RA   Schmokel H.G., Willey S., Hicklin D.J., Pytowski B., Swartz M.A.;
RT   "Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in
RT   adult lymphangiogenesis.";
RL   FASEB J. 21:1003-1012(2007).
RN   [24]
RP   ROLE IN CANCER, FUNCTION AS VEGFC RECEPTOR IN TUMOR LYMPHANGIOGENESIS;
RP   CELL PROLIFERATION; CELL SURVIVAL; IN ACTIVATION OF PIK3R1; AKT1 AND
RP   MAP KINASES AND IN UP-REGULATION OF VEGFA AND VEGFC EXPRESSION, ENZYME
RP   REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=19779139; DOI=10.2353/ajpath.2009.081139;
RA   Matsuura M., Onimaru M., Yonemitsu Y., Suzuki H., Nakano T.,
RA   Ishibashi H., Shirasuna K., Sueishi K.;
RT   "Autocrine loop between vascular endothelial growth factor (VEGF)-C
RT   and VEGF receptor-3 positively regulates tumor-associated
RT   lymphangiogenesis in oral squamoid cancer cells.";
RL   Am. J. Pathol. 175:1709-1721(2009).
RN   [25]
RP   ROLE IN CANCER, AND INTERACTION WITH PTK2/FAK1.
RX   PubMed=19610651; DOI=10.1021/jm900159g;
RA   Kurenova E.V., Hunt D.L., He D., Magis A.T., Ostrov D.A., Cance W.G.;
RT   "Small molecule chloropyramine hydrochloride (C4) targets the binding
RT   site of focal adhesion kinase and vascular endothelial growth factor
RT   receptor 3 and suppresses breast cancer growth in vivo.";
RL   J. Med. Chem. 52:4716-4724(2009).
RN   [26]
RP   INTERACTION WITH PTPN14.
RX   PubMed=20826270; DOI=10.1016/j.ajhg.2010.08.008;
RA   Au A.C., Hernandez P.A., Lieber E., Nadroo A.M., Shen Y.M.,
RA   Kelley K.A., Gelb B.D., Diaz G.A.;
RT   "Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic
RT   function and choanal development in humans.";
RL   Am. J. Hum. Genet. 87:436-444(2010).
RN   [27]
RP   PHOSPHORYLATION AT TYR-830; TYR-833; TYR-853; TYR-1063; TYR-1068;
RP   TYR-1333 AND TYR-1337, IDENTIFICATION IN A COMPLEX WITH SRC AND ITGB1,
RP   MUTAGENESIS OF TYR-1063; TYR-1068 AND TYR-1337, ENZYME REGULATION BY
RP   MAZ51, INTERACTION WITH ITGB1; CRK AND SHC1, FUNCTION IN ACTIVATION OF
RP   MAPK8 AND IN REGULATION OF ANGIOGENIC SPROUTING, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=20431062; DOI=10.1161/CIRCRESAHA.109.206326;
RA   Galvagni F., Pennacchini S., Salameh A., Rocchigiani M., Neri F.,
RA   Orlandini M., Petraglia F., Gotta S., Sardone G.L., Matteucci G.,
RA   Terstappen G.C., Oliviero S.;
RT   "Endothelial cell adhesion to the extracellular matrix induces c-Src-
RT   dependent VEGFR-3 phosphorylation without the activation of the
RT   receptor intrinsic kinase activity.";
RL   Circ. Res. 106:1839-1848(2010).
RN   [28]
RP   INTERACTION WITH KDR, FUNCTION IN MODULATING KDR SIGNALING AND IN
RP   ANGIOGENESIS, AND TISSUE SPECIFICITY.
RX   PubMed=20224550; DOI=10.1038/emboj.2010.30;
RA   Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M.,
RA   Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M.,
RA   Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L.;
RT   "VEGF receptor 2/-3 heterodimers detected in situ by proximity
RT   ligation on angiogenic sprouts.";
RL   EMBO J. 29:1377-1388(2010).
RN   [29]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20445537; DOI=10.1038/nature09002;
RA   Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L.,
RA   Sakakibara A., Adams S., Davy A., Deutsch U., Luthi U., Barberis A.,
RA   Benjamin L.E., Makinen T., Nobes C.D., Adams R.H.;
RT   "Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.";
RL   Nature 465:483-486(2010).
RN   [30]
RP   FUNCTION IN LYMPHANGIOGENESIS.
RX   PubMed=21273538; DOI=10.1167/iovs.10-6408;
RA   Yuen D., Pytowski B., Chen L.;
RT   "Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory
RT   lymphangiogenesis in early and middle stages.";
RL   Invest. Ophthalmol. Vis. Sci. 52:2593-2597(2011).
RN   [31]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [32]
RP   REVIEW ON ROLE IN LYMPHANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus
RT   lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [33]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/BJ20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor
RT   receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [34]
RP   REVIEW ON FUNCTION IN LYMPHANGIOGENESIS AND ROLE IN CANCER.
RX   PubMed=21196198; DOI=10.2741/3715;
RA   Al-Rawi M.A., Jiang W.G.;
RT   "Lymphangiogenesis and cancer metastasis.";
RL   Front. Biosci. 16:723-739(2011).
RN   [35]
RP   VARIANT LMPH1A LEU-1114.
RX   PubMed=9817924; DOI=10.1093/hmg/7.13.2073;
RA   Ferrell R.E., Levinson K.L., Esman J.H., Kimak M.A., Lawrence E.C.,
RA   Barmada M.M., Finegold D.N.;
RT   "Hereditary lymphedema: evidence for linkage and genetic
RT   heterogeneity.";
RL   Hum. Mol. Genet. 7:2073-2078(1998).
RN   [36]
RP   INVOLVEMENT IN LMPH1A, AND CHARACTERIZATION OF VARIANT LMPH1A
RP   ARG-1035.
RX   PubMed=10856194; DOI=10.1086/303019;
RA   Irrthum A., Karkkainen M.J., Devriendt K., Alitalo K., Vikkula M.;
RT   "Congenital hereditary lymphedema caused by a mutation that
RT   inactivates VEGFR3 tyrosine kinase.";
RL   Am. J. Hum. Genet. 67:295-301(2000).
RN   [37]
RP   VARIANTS LMPH1A ARG-857; PRO-1041; PRO-1044 AND LEU-1114, VARIANT
RP   SER-641, AND CHARACTERIZATION OF VARIANTS.
RX   PubMed=10835628; DOI=10.1038/75997;
RA   Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A.,
RA   Levinson K.L., McTigue M.A., Alitalo K., Finegold D.N.;
RT   "Missense mutations interfere with VEGFR-3 signalling in primary
RT   lymphoedema.";
RL   Nat. Genet. 25:153-159(2000).
RN   [38]
RP   VARIANTS HCI SER-954 AND SER-1137, AND VARIANTS ALA-494; GLN-890 AND
RP   HIS-1146.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F.,
RA   Walker J.W.T., Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [39]
RP   VARIANTS LMPH1A MET-878; THR-1086 AND PHE-1108 DEL, VARIANT GLN-1035,
RP   AND INVOLVEMENT IN LMPH1A.
RX   PubMed=16965327; DOI=10.1111/j.1399-0004.2006.00687.x;
RA   Ghalamkarpour A., Morlot S., Raas-Rothschild A., Utkus A.,
RA   Mulliken J.B., Boon L.M., Vikkula M.;
RT   "Hereditary lymphedema type I associated with VEGFR3 mutation: the
RT   first de novo case and atypical presentations.";
RL   Clin. Genet. 70:330-335(2006).
RN   [40]
RP   VARIANT LMPH1A LYS-1106, AND INVOLVEMENT IN LMPH1A.
RX   PubMed=16924388; DOI=10.1007/s10038-006-0031-3;
RA   Spiegel R., Ghalamkarpour A., Daniel-Spiegel E., Vikkula M.,
RA   Shalev S.A.;
RT   "Wide clinical spectrum in a family with hereditary lymphedema type I
RT   due to a novel missense mutation in VEGFR3.";
RL   J. Hum. Genet. 51:846-850(2006).
RN   [41]
RP   VARIANT LMPH1A LEU-1020.
RX   PubMed=17458866; DOI=10.1002/ajmg.a.31703;
RA   Butler M.G., Dagenais S.L., Rockson S.G., Glover T.W.;
RT   "A novel VEGFR3 mutation causes Milroy disease.";
RL   Am. J. Med. Genet. A 143A:1212-1217(2007).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-149; CYS-378; ALA-494; SER-527;
RP   SER-641; TYR-868; ILE-1010; GLN-1031; ASN-1049; GLN-1075 AND HIS-1146.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [43]
RP   VARIANT LMPH1A THR-855, AND CHARACTERIZATION OF VARIANT LMPH1A
RP   THR-855.
RX   PubMed=19289394; DOI=10.1136/jmg.2008.064469;
RA   Ghalamkarpour A., Holnthoner W., Saharinen P., Boon L.M.,
RA   Mulliken J.B., Alitalo K., Vikkula M.;
RT   "Recessive primary congenital lymphoedema caused by a VEGFR3
RT   mutation.";
RL   J. Med. Genet. 46:399-404(2009).
RN   [44]
RP   VARIANT LMPH1A CYS-1235.
RX   PubMed=26091405; DOI=10.1089/lrb.2014.0044;
RA   Melikhan-Revzin S., Kurolap A., Dagan E., Mory A., Gershoni-Baruch R.;
RT   "A novel missense mutation in FLT4 causes autosomal recessive
RT   hereditary lymphedema.";
RL   Lymphat. Res. Biol. 13:107-111(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFC and VEGFD, and plays an essential role in adult
CC       lymphangiogenesis and in the development of the vascular network
CC       and the cardiovascular system during embryonic development.
CC       Promotes proliferation, survival and migration of endothelial
CC       cells, and regulates angiogenic sprouting. Signaling by activated
CC       FLT4 leads to enhanced production of VEGFC, and to a lesser degree
CC       VEGFA, thereby creating a positive feedback loop that enhances
CC       FLT4 signaling. Modulates KDR signaling by forming heterodimers.
CC       The secreted isoform 3 may function as a decoy receptor for VEGFC
CC       and/or VEGFD and play an important role as a negative regulator of
CC       VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of
CC       vascular growth factors to isoform 1 or isoform 2 leads to the
CC       activation of several signaling cascades; isoform 2 seems to be
CC       less efficient in signal transduction, because it has a truncated
CC       C-terminus and therefore lacks several phosphorylation sites.
CC       Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling
CC       pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1
CC       signaling pathway. Phosphorylates SHC1. Mediates phosphorylation
CC       of PIK3R1, the regulatory subunit of phosphatidylinositol 3-
CC       kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-
CC       185', and of AKT1 at 'Ser-473'. {ECO:0000269|PubMed:11532940,
CC       ECO:0000269|PubMed:15102829, ECO:0000269|PubMed:15474514,
CC       ECO:0000269|PubMed:16076871, ECO:0000269|PubMed:16452200,
CC       ECO:0000269|PubMed:17210781, ECO:0000269|PubMed:19610651,
CC       ECO:0000269|PubMed:19779139, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:20445537,
CC       ECO:0000269|PubMed:21273538, ECO:0000269|PubMed:7675451,
CC       ECO:0000269|PubMed:8700872, ECO:0000269|PubMed:9435229}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12881528,
CC       ECO:0000269|PubMed:7898938}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFC or VEGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by MAZ51. {ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:19779139, ECO:0000269|PubMed:20431062}.
CC   -!- SUBUNIT: Interacts with VEGFC and VEGFD. Monomer in the absence of
CC       bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or
CC       VEGFD. Can also form a heterodimer with KDR. Interacts with
CC       PTPN14; the interaction is enhanced by stimulation with VEGFC.
CC       Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-
CC       2. Identified in a complex with SRC and ITGB1.
CC       {ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:15474514, ECO:0000269|PubMed:16076871,
CC       ECO:0000269|PubMed:16452200, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:19610651, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:20826270,
CC       ECO:0000269|PubMed:7675451, ECO:0000269|PubMed:8700872,
CC       ECO:0000269|PubMed:9435229}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1005467, EBI-352572;
CC       P35968:KDR; NbExp=5; IntAct=EBI-1005467, EBI-1005487;
CC       P49767:VEGFC; NbExp=2; IntAct=EBI-1005467, EBI-3405539;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasm. Nucleus. Note=Ligand-mediated
CC       autophosphorylation leads to rapid internalization.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Note=Ligand-mediated autophosphorylation leads
CC       to rapid internalization.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=P35916-2; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P35916-1; Sequence=VSP_041995;
CC       Name=3; Synonyms=sVegfr3;
CC         IsoId=P35916-3; Sequence=VSP_041993, VSP_041994;
CC   -!- TISSUE SPECIFICITY: Detected in endothelial cells (at protein
CC       level). Widely expressed. Detected in fetal spleen, lung and
CC       brain. Detected in adult liver, muscle, thymus, placenta, lung,
CC       testis, ovary, prostate, heart, and kidney.
CC       {ECO:0000269|PubMed:1327515, ECO:0000269|PubMed:20224550,
CC       ECO:0000269|PubMed:7675451}.
CC   -!- DOMAIN: The first and second Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFC binding.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation in response to H(2)O(2) is mediated by a
CC       process that requires SRC and PRKCD activity. Phosphorylation at
CC       Tyr-1068 is required for autophosphorylation at additional
CC       tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is
CC       important for interaction with CRK and subsequent activation of
CC       MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is
CC       important for interaction with GRB2 and subsequent activation of
CC       the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In
CC       response to endothelial cell adhesion onto collagen, can also be
CC       phosphorylated in the absence of FLT4 kinase activity by SRC at
CC       Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337.
CC       {ECO:0000269|PubMed:12881528, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:15474514, ECO:0000269|PubMed:16076871,
CC       ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:8700872}.
CC   -!- DISEASE: Lymphedema, hereditary, 1A (LMPH1A) [MIM:153100]: A
CC       chronic disabling condition which results in swelling of the
CC       extremities due to altered lymphatic flow. Patients with
CC       lymphedema suffer from recurrent local infections and physical
CC       impairment. {ECO:0000269|PubMed:10835628,
CC       ECO:0000269|PubMed:10856194, ECO:0000269|PubMed:12881528,
CC       ECO:0000269|PubMed:15102829, ECO:0000269|PubMed:16924388,
CC       ECO:0000269|PubMed:16965327, ECO:0000269|PubMed:17458866,
CC       ECO:0000269|PubMed:19289394, ECO:0000269|PubMed:26091405,
CC       ECO:0000269|PubMed:9817924}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A
CC       condition characterized by dull red, firm, dome-shaped
CC       hemangiomas, sharply demarcated from surrounding skin, usually
CC       presenting at birth or occurring within the first two or three
CC       months of life. They result from highly proliferative, localized
CC       growth of capillary endothelium and generally undergo regression
CC       and involution without scarring. {ECO:0000269|PubMed:11807987}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Plays an important role in tumor lymphangiogenesis,
CC       in cancer cell survival, migration, and formation of metastases.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA48290.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=FLT4 entry;
CC       URL="https://en.wikipedia.org/wiki/FLT4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X69878; CAA49505.1; -; mRNA.
DR   EMBL; U43143; AAA85215.1; -; mRNA.
DR   EMBL; EU826564; ACF47600.1; -; mRNA.
DR   EMBL; AY233382; AAO89504.1; -; mRNA.
DR   EMBL; AY233383; AAO89505.1; -; mRNA.
DR   EMBL; AK291679; BAF84368.1; -; mRNA.
DR   EMBL; AC122714; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X68203; CAA48290.1; ALT_INIT; mRNA.
DR   EMBL; S66407; AAB28539.1; -; mRNA.
DR   CCDS; CCDS43412.1; -. [P35916-1]
DR   CCDS; CCDS4457.1; -. [P35916-2]
DR   PIR; A48999; A48999.
DR   RefSeq; NP_002011.2; NM_002020.4. [P35916-1]
DR   RefSeq; NP_891555.2; NM_182925.4. [P35916-2]
DR   UniGene; Hs.646917; -.
DR   PDB; 4BSJ; X-ray; 2.50 A; A=330-553.
DR   PDB; 4BSK; X-ray; 4.20 A; A=23-229.
DR   PDBsum; 4BSJ; -.
DR   PDBsum; 4BSK; -.
DR   ProteinModelPortal; P35916; -.
DR   SMR; P35916; -.
DR   BioGrid; 108612; 23.
DR   DIP; DIP-5739N; -.
DR   IntAct; P35916; 7.
DR   MINT; MINT-1182429; -.
DR   STRING; 9606.ENSP00000261937; -.
DR   BindingDB; P35916; -.
DR   ChEMBL; CHEMBL1955; -.
DR   DrugBank; DB06080; ABT-869.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB06101; IMC-1C11.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05075; TG100801.
DR   DrugBank; DB04879; Vatalanib.
DR   GuidetoPHARMACOLOGY; 1814; -.
DR   iPTMnet; P35916; -.
DR   PhosphoSitePlus; P35916; -.
DR   BioMuta; FLT4; -.
DR   DMDM; 357529070; -.
DR   PaxDb; P35916; -.
DR   PeptideAtlas; P35916; -.
DR   PRIDE; P35916; -.
DR   DNASU; 2324; -.
DR   Ensembl; ENST00000261937; ENSP00000261937; ENSG00000037280. [P35916-2]
DR   Ensembl; ENST00000393347; ENSP00000377016; ENSG00000037280. [P35916-1]
DR   GeneID; 2324; -.
DR   KEGG; hsa:2324; -.
DR   UCSC; uc003mlz.4; human. [P35916-2]
DR   CTD; 2324; -.
DR   DisGeNET; 2324; -.
DR   GeneCards; FLT4; -.
DR   GeneReviews; FLT4; -.
DR   HGNC; HGNC:3767; FLT4.
DR   HPA; CAB000099; -.
DR   MalaCards; FLT4; -.
DR   MIM; 136352; gene.
DR   MIM; 153100; phenotype.
DR   MIM; 602089; phenotype.
DR   neXtProt; NX_P35916; -.
DR   OpenTargets; ENSG00000037280; -.
DR   Orphanet; 79452; Milroy disease.
DR   PharmGKB; PA28183; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000037949; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P35916; -.
DR   KO; K05097; -.
DR   OMA; CDTVAVK; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P35916; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   SignaLink; P35916; -.
DR   SIGNOR; P35916; -.
DR   ChiTaRS; FLT4; human.
DR   GeneWiki; FLT4; -.
DR   GenomeRNAi; 2324; -.
DR   PRO; PR:P35916; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000037280; -.
DR   CleanEx; HS_FLT4; -.
DR   ExpressionAtlas; P35916; baseline and differential.
DR   Genevisible; P35916; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:MGI.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0001945; P:lymph vessel development; ISS:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0060312; P:regulation of blood vessel remodeling; ISS:UniProtKB.
DR   GO; GO:0003016; P:respiratory system process; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0001944; P:vasculature development; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009137; VEGFR3_rcpt.
DR   PANTHER; PTHR24416:SF438; PTHR24416:SF438; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   SMART; SM00409; IG; 6.
DR   SMART; SM00408; IGc2; 4.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 6.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        25   1363       Vascular endothelial growth factor
FT                                receptor 3.
FT                                /FTId=PRO_0000016776.
FT   TOPO_DOM     25    775       Extracellular. {ECO:0000255}.
FT   TRANSMEM    776    796       Helical. {ECO:0000255}.
FT   TOPO_DOM    797   1363       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       30    127       Ig-like C2-type 1.
FT   DOMAIN      151    213       Ig-like C2-type 2.
FT   DOMAIN      219    326       Ig-like C2-type 3.
FT   DOMAIN      331    415       Ig-like C2-type 4.
FT   DOMAIN      422    552       Ig-like C2-type 5.
FT   DOMAIN      555    671       Ig-like C2-type 6.
FT   DOMAIN      678    764       Ig-like C2-type 7.
FT   DOMAIN      845   1173       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     851    859       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1037   1037       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     879    879       ATP. {ECO:0000305}.
FT   MOD_RES     830    830       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES     833    833       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES     853    853       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1063   1063       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1068   1068       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1230   1230       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MOD_RES    1231   1231       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MOD_RES    1265   1265       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MOD_RES    1333   1333       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1337   1337       Phosphotyrosine; by autocatalysis and
FT                                SRC. {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MOD_RES    1363   1363       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12881528}.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    104    104       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    166    166       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    251    251       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    299    299       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    515    515       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    527    527       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    594    594       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    683    683       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    758    758       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     51    111       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    158    206       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    252    310       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    445    534       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    578    653       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    699    751       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     724    765       VDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVA
FT                                V -> REGGPGEGQVRRPARPTIPNPGGPAPPPHPLQESTW
FT                                RTPTRS (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041993.
FT   VAR_SEQ     766   1298       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041994.
FT   VAR_SEQ    1298   1363       SCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYG
FT                                ELSEPSEEDHCSPSARVTFFTDNSY -> R (in
FT                                isoform 2). {ECO:0000303|PubMed:1319394,
FT                                ECO:0000303|PubMed:1327515,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:8386825,
FT                                ECO:0000303|PubMed:8700872,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041995.
FT   VARIANT     149    149       N -> D (in dbSNP:rs34221241).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042062.
FT   VARIANT     378    378       R -> C (in a renal clear cell carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs372947534).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042063.
FT   VARIANT     494    494       T -> A (in dbSNP:rs307826).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018407.
FT   VARIANT     527    527       N -> S (in dbSNP:rs35874891).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034379.
FT   VARIANT     641    641       P -> S (in dbSNP:rs55667289).
FT                                {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018408.
FT   VARIANT     855    855       A -> T (in LMPH1A; recessive form;
FT                                results in reduced autophosphorylation;
FT                                results in impaired ligand-induced
FT                                receptor internalisation and downstream
FT                                signaling; dbSNP:rs121909657).
FT                                {ECO:0000269|PubMed:19289394}.
FT                                /FTId=VAR_074044.
FT   VARIANT     857    857       G -> R (in LMPH1A; loss of kinase
FT                                activity; dbSNP:rs267606818).
FT                                {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:15102829}.
FT                                /FTId=VAR_018409.
FT   VARIANT     868    868       H -> Y (in dbSNP:rs35171798).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042064.
FT   VARIANT     878    878       V -> M (in LMPH1A; dbSNP:rs121909654).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074045.
FT   VARIANT     890    890       H -> Q (in dbSNP:rs448012).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:8386825,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_018410.
FT   VARIANT     954    954       P -> S (in HCI; dbSNP:rs34255532).
FT                                {ECO:0000269|PubMed:11807987}.
FT                                /FTId=VAR_018411.
FT   VARIANT    1010   1010       T -> I (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042065.
FT   VARIANT    1020   1020       Q -> L (in LMPH1A).
FT                                {ECO:0000269|PubMed:17458866}.
FT                                /FTId=VAR_074046.
FT   VARIANT    1031   1031       R -> Q (in dbSNP:rs56082504).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042066.
FT   VARIANT    1035   1035       H -> Q (probable disease-associated
FT                                mutation found in sporadic congenital
FT                                lymphedema; de novo mutation).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074047.
FT   VARIANT    1035   1035       H -> R (in LMPH1A; loss of kinase
FT                                activity; dbSNP:rs121909653).
FT                                {ECO:0000269|PubMed:10856194}.
FT                                /FTId=VAR_018412.
FT   VARIANT    1041   1041       R -> P (in LMPH1A; loss of kinase
FT                                activity; dbSNP:rs121909650).
FT                                {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:12881528}.
FT                                /FTId=VAR_018413.
FT   VARIANT    1044   1044       L -> P (in LMPH1A; loss of kinase
FT                                activity; dbSNP:rs121909651).
FT                                {ECO:0000269|PubMed:10835628}.
FT                                /FTId=VAR_018414.
FT   VARIANT    1049   1049       D -> N (in dbSNP:rs56310180).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042067.
FT   VARIANT    1075   1075       R -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042068.
FT   VARIANT    1086   1086       I -> T (in LMPH1A; dbSNP:rs121909655).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074048.
FT   VARIANT    1106   1106       E -> K (in LMPH1A; dbSNP:rs121909656).
FT                                {ECO:0000269|PubMed:16924388}.
FT                                /FTId=VAR_074049.
FT   VARIANT    1108   1108       Missing (in LMPH1A).
FT                                {ECO:0000269|PubMed:16965327}.
FT                                /FTId=VAR_074050.
FT   VARIANT    1114   1114       P -> L (in LMPH1A; loss of kinase
FT                                activity; dbSNP:rs121909652).
FT                                {ECO:0000269|PubMed:10835628,
FT                                ECO:0000269|PubMed:9817924}.
FT                                /FTId=VAR_018415.
FT   VARIANT    1137   1137       P -> S (in HCI).
FT                                {ECO:0000269|PubMed:11807987}.
FT                                /FTId=VAR_018416.
FT   VARIANT    1146   1146       R -> H (in dbSNP:rs1130379).
FT                                {ECO:0000269|PubMed:11807987,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8386825,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_018417.
FT   VARIANT    1235   1235       S -> C (in LMPH1A; recessive form).
FT                                {ECO:0000269|PubMed:26091405}.
FT                                /FTId=VAR_074051.
FT   MUTAGEN     879    879       K->G: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MUTAGEN    1063   1063       Y->F: Loss of phosphorylation site. No
FT                                effect on stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MUTAGEN    1068   1068       Y->F: Global loss of autophosphorylation.
FT                                Abolishes stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:16076871,
FT                                ECO:0000269|PubMed:20431062}.
FT   MUTAGEN    1230   1230       Y->F: Loss of phosphorylation site.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MUTAGEN    1231   1231       Y->F: Loss of phosphorylation site.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:16076871}.
FT   MUTAGEN    1265   1265       Y->F: Loss of phosphorylation site. No
FT                                effect on stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528}.
FT   MUTAGEN    1333   1333       Y->F: Loss of phosphorylation site.
FT                                Reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:7675451}.
FT   MUTAGEN    1337   1337       Y->F: Reduced autophosphorylation.
FT                                Strongly reduces stimulation of cell
FT                                proliferation and cell migration.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:20431062,
FT                                ECO:0000269|PubMed:7675451}.
FT   MUTAGEN    1363   1363       Y->F: Loss of phosphorylation site.
FT                                Slighly reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:12881528,
FT                                ECO:0000269|PubMed:7675451}.
FT   CONFLICT     24     24       G -> D (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT    538    538       N -> D (in Ref. 8; BAF84368).
FT                                {ECO:0000305}.
FT   CONFLICT    745    745       R -> P (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT    752    753       NA -> RP (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT   1128   1128       L -> V (in Ref. 3; CAA49505 and 7;
FT                                AAO89504/AAO89505). {ECO:0000305}.
FT   CONFLICT   1164   1164       E -> D (in Ref. 3; CAA49505).
FT                                {ECO:0000305}.
FT   STRAND      332    339       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      341    346       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      350    362       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      365    370       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      381    388       {ECO:0000244|PDB:4BSJ}.
FT   HELIX       391    393       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      395    403       {ECO:0000244|PDB:4BSJ}.
FT   TURN        404    407       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      408    424       {ECO:0000244|PDB:4BSJ}.
FT   HELIX       425    428       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      441    451       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      457    464       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      501    511       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      514    524       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      530    538       {ECO:0000244|PDB:4BSJ}.
FT   STRAND      541    549       {ECO:0000244|PDB:4BSJ}.
SQ   SEQUENCE   1363 AA;  152757 MW;  B1473AAAC95E7E93 CRC64;
     MQRGAALCLR LWLCLGLLDG LVSGYSMTPP TLNITEESHV IDTGDSLSIS CRGQHPLEWA
     WPGAQEAPAT GDKDSEDTGV VRDCEGTDAR PYCKVLLLHE VHANDTGSYV CYYKYIKARI
     EGTTAASSYV FVRDFEQPFI NKPDTLLVNR KDAMWVPCLV SIPGLNVTLR SQSSVLWPDG
     QEVVWDDRRG MLVSTPLLHD ALYLQCETTW GDQDFLSNPF LVHITGNELY DIQLLPRKSL
     ELLVGEKLVL NCTVWAEFNS GVTFDWDYPG KQAERGKWVP ERRSQQTHTE LSSILTIHNV
     SQHDLGSYVC KANNGIQRFR ESTEVIVHEN PFISVEWLKG PILEATAGDE LVKLPVKLAA
     YPPPEFQWYK DGKALSGRHS PHALVLKEVT EASTGTYTLA LWNSAAGLRR NISLELVVNV
     PPQIHEKEAS SPSIYSRHSR QALTCTAYGV PLPLSIQWHW RPWTPCKMFA QRSLRRRQQQ
     DLMPQCRDWR AVTTQDAVNP IESLDTWTEF VEGKNKTVSK LVIQNANVSA MYKCVVSNKV
     GQDERLIYFY VTTIPDGFTI ESKPSEELLE GQPVLLSCQA DSYKYEHLRW YRLNLSTLHD
     AHGNPLLLDC KNVHLFATPL AASLEEVAPG ARHATLSLSI PRVAPEHEGH YVCEVQDRRS
     HDKHCHKKYL SVQALEAPRL TQNLTDLLVN VSDSLEMQCL VAGAHAPSIV WYKDERLLEE
     KSGVDLADSN QKLSIQRVRE EDAGRYLCSV CNAKGCVNSS ASVAVEGSED KGSMEIVILV
     GTGVIAVFFW VLLLLIFCNM RRPAHADIKT GYLSIIMDPG EVPLEEQCEY LSYDASQWEF
     PRERLHLGRV LGYGAFGKVV EASAFGIHKG SSCDTVAVKM LKEGATASEH RALMSELKIL
     IHIGNHLNVV NLLGACTKPQ GPLMVIVEFC KYGNLSNFLR AKRDAFSPCA EKSPEQRGRF
     RAMVELARLD RRRPGSSDRV LFARFSKTEG GARRASPDQE AEDLWLSPLT MEDLVCYSFQ
     VARGMEFLAS RKCIHRDLAA RNILLSESDV VKICDFGLAR DIYKDPDYVR KGSARLPLKW
     MAPESIFDKV YTTQSDVWSF GVLLWEIFSL GASPYPGVQI NEEFCQRLRD GTRMRAPELA
     TPAIRRIMLN CWSGDPKARP AFSELVEILG DLLQGRGLQE EEEVCMAPRS SQSSEEGSFS
     QVSTMALHIA QADAEDSPPS LQRHSLAARY YNWVSFPGCL ARGAETRGSS RMKTFEEFPM
     TPTTYKGSVD NQTDSGMVLA SEEFEQIESR HRQESGFSCK GPGQNVAVTR AHPDSQGRRR
     RPERGARGGQ VFYNSEYGEL SEPSEEDHCS PSARVTFFTD NSY
//
